Candel Therapeutics IncNASDAQ:CADL
- LAST PRICE4.8300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.7200/ 1
- Ask / Lots5.2600/ 23
- Open / Previous Close--- / 4.8300
- Day Range---
- 52 Week Range
- Volume386
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CADL |
|---|---|---|
| 09:32 ET | 6984 | 5.14 |
| 09:33 ET | 13906 | 5.0309 |
| 09:35 ET | 3808 | 5.045 |
| 09:37 ET | 25983 | 4.9702 |
| 09:39 ET | 10897 | 4.95 |
| 09:42 ET | 450 | 4.98 |
| 09:44 ET | 14775 | 4.8851 |
| 09:46 ET | 2649 | 4.96 |
| 09:48 ET | 9740 | 4.98 |
| 09:51 ET | 1000 | 4.9885 |
| 09:53 ET | 1000 | 4.9899 |
| 09:55 ET | 100 | 4.965 |
| 09:57 ET | 1040 | 4.965 |
| 10:00 ET | 1458 | 4.9595 |
| 10:02 ET | 1299 | 4.96 |
| 10:04 ET | 200 | 4.9853 |
| 10:06 ET | 550 | 4.9508 |
| 10:09 ET | 532 | 4.955 |
| 10:11 ET | 1006 | 4.97 |
| 10:13 ET | 18459 | 5 |
| 10:15 ET | 324 | 4.98 |
| 10:18 ET | 100 | 4.96 |
| 10:20 ET | 600 | 4.97 |
| 10:22 ET | 100 | 4.96 |
| 10:24 ET | 200 | 4.96 |
| 10:26 ET | 500 | 4.96 |
| 10:27 ET | 200 | 4.94 |
| 10:29 ET | 3075 | 4.9302 |
| 10:31 ET | 2141 | 4.92 |
| 10:36 ET | 633 | 4.945 |
| 10:38 ET | 1400 | 4.93 |
| 10:42 ET | 4069 | 4.95 |
| 10:47 ET | 3240 | 4.96 |
| 10:49 ET | 600 | 4.93 |
| 10:51 ET | 600 | 4.9437 |
| 10:54 ET | 100 | 4.9646 |
| 10:56 ET | 1100 | 4.935 |
| 10:58 ET | 5900 | 4.94 |
| 11:03 ET | 200 | 4.945 |
| 11:09 ET | 100 | 4.93 |
| 11:14 ET | 520 | 4.93 |
| 11:16 ET | 9714 | 4.94 |
| 11:18 ET | 3817 | 4.9201 |
| 11:20 ET | 100 | 4.93 |
| 11:23 ET | 995 | 4.98 |
| 11:25 ET | 1581 | 4.9999 |
| 11:27 ET | 318 | 4.99 |
| 11:30 ET | 270 | 4.99 |
| 11:32 ET | 100 | 4.99 |
| 11:34 ET | 1564 | 5 |
| 11:36 ET | 839 | 4.95 |
| 11:38 ET | 100 | 4.95 |
| 11:39 ET | 3930 | 4.925 |
| 11:41 ET | 4500 | 4.9278 |
| 11:43 ET | 2100 | 4.9395 |
| 11:45 ET | 1100 | 4.925 |
| 11:48 ET | 1100 | 4.92 |
| 11:52 ET | 100 | 4.925 |
| 11:54 ET | 800 | 4.9352 |
| 11:56 ET | 1300 | 4.92 |
| 11:57 ET | 5279 | 4.91 |
| 11:59 ET | 1472 | 4.8962 |
| 12:01 ET | 1587 | 4.93 |
| 12:03 ET | 1100 | 4.93 |
| 12:08 ET | 200 | 4.925 |
| 12:10 ET | 100 | 4.925 |
| 12:12 ET | 901 | 4.91 |
| 12:14 ET | 3100 | 4.92 |
| 12:15 ET | 14755 | 4.83 |
| 12:17 ET | 1428 | 4.86 |
| 12:19 ET | 100 | 4.855 |
| 12:21 ET | 2770 | 4.8601 |
| 12:24 ET | 240 | 4.875 |
| 12:26 ET | 100 | 4.865 |
| 12:28 ET | 2816 | 4.88 |
| 12:32 ET | 250 | 4.87 |
| 12:33 ET | 445 | 4.86 |
| 12:37 ET | 100 | 4.86 |
| 12:42 ET | 628 | 4.86 |
| 12:46 ET | 600 | 4.88 |
| 12:48 ET | 1429 | 4.88 |
| 12:50 ET | 100 | 4.9 |
| 12:51 ET | 100 | 4.9081 |
| 12:55 ET | 2436 | 4.89 |
| 01:00 ET | 890 | 4.9 |
| 01:02 ET | 100 | 4.9 |
| 01:04 ET | 280 | 4.9 |
| 01:06 ET | 201 | 4.8997 |
| 01:09 ET | 2300 | 4.91 |
| 01:11 ET | 100 | 4.91 |
| 01:13 ET | 369 | 4.91 |
| 01:15 ET | 100 | 4.9189 |
| 01:18 ET | 1100 | 4.915 |
| 01:20 ET | 4901 | 4.91 |
| 01:26 ET | 3200 | 4.89 |
| 01:27 ET | 2000 | 4.915 |
| 01:31 ET | 340 | 4.9341 |
| 01:36 ET | 2100 | 4.925 |
| 01:40 ET | 100 | 4.93 |
| 01:42 ET | 400 | 4.93 |
| 01:45 ET | 1422 | 4.9201 |
| 01:49 ET | 1160 | 4.91 |
| 01:58 ET | 552 | 4.91 |
| 02:00 ET | 2389 | 4.92 |
| 02:02 ET | 100 | 4.92 |
| 02:03 ET | 100 | 4.92 |
| 02:05 ET | 557 | 4.91 |
| 02:12 ET | 1500 | 4.88 |
| 02:14 ET | 6098 | 4.89 |
| 02:16 ET | 1700 | 4.9178 |
| 02:18 ET | 1100 | 4.872 |
| 02:20 ET | 100 | 4.87 |
| 02:21 ET | 517 | 4.8799 |
| 02:23 ET | 500 | 4.87 |
| 02:25 ET | 1270 | 4.86 |
| 02:32 ET | 2118 | 4.88 |
| 02:34 ET | 200 | 4.89 |
| 02:36 ET | 1194 | 4.9 |
| 02:38 ET | 912 | 4.94 |
| 02:39 ET | 100 | 4.93 |
| 02:41 ET | 2904 | 4.93 |
| 02:45 ET | 800 | 4.93 |
| 02:50 ET | 200 | 4.93 |
| 02:52 ET | 1684 | 4.94 |
| 02:54 ET | 1211 | 4.935 |
| 02:56 ET | 1100 | 4.94 |
| 02:59 ET | 620 | 4.93 |
| 03:01 ET | 1100 | 4.935 |
| 03:06 ET | 9729 | 4.955 |
| 03:08 ET | 200 | 4.955 |
| 03:10 ET | 503 | 4.955 |
| 03:14 ET | 3871 | 4.9459 |
| 03:15 ET | 1999 | 4.95 |
| 03:17 ET | 300 | 4.95 |
| 03:19 ET | 633 | 4.94 |
| 03:24 ET | 745 | 4.92 |
| 03:26 ET | 1100 | 4.91 |
| 03:30 ET | 230 | 4.92 |
| 03:32 ET | 1040 | 4.911489 |
| 03:33 ET | 3861 | 4.9 |
| 03:35 ET | 1000 | 4.9103 |
| 03:37 ET | 8982 | 4.89 |
| 03:39 ET | 4951 | 4.87 |
| 03:42 ET | 200 | 4.87 |
| 03:44 ET | 1300 | 4.87 |
| 03:46 ET | 8200 | 4.86 |
| 03:48 ET | 3671 | 4.87 |
| 03:50 ET | 5257 | 4.87 |
| 03:51 ET | 5171 | 4.873224 |
| 03:53 ET | 900 | 4.885 |
| 03:55 ET | 1400 | 4.88 |
| 03:57 ET | 12265 | 4.86 |
| 04:00 ET | 28666 | 4.83 |
Nov 7, 2024
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024, from 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 5, 2024
Oct 28, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Candel Therapeutics Inc | 155.0M | -2.8x | --- |
Ventyx Biosciences Inc | 155.5M | -0.9x | --- |
Checkpoint Therapeutics Inc | 151.7M | -2.2x | --- |
Achieve Life Sciences Inc | 159.0M | -4.2x | --- |
Cytodyn Inc | 150.0M | -5.1x | --- |
Outlook Therapeutics Inc | 149.5M | -0.8x | --- |
Company Information
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Contact Information
- Headquarters
- 117 Kendrick Street,, Suite 450NEEDHAM, MA, United States 02494
- Phone
- 617-916-5445
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Paul Manning
- President, Chief Executive Officer, Director
- Paul Tak
- Interim Chief Financial Officer
- Charles Schoch
- Chief Scientific Officer
- Francesca Barone
- Chief Medical Officer
- W. Garrett Nichols
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $155.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 32.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.92 |
EPS | $-1.70 |
Book Value | $0.44 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
